Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of “Buy” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given an average rating of “Buy” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company.

A number of research analysts have commented on BAYRY shares. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Finally, Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd.

Bayer Aktiengesellschaft Trading Up 1.4%

Shares of BAYRY stock opened at $12.68 on Thursday. The firm has a fifty day moving average of $10.27 and a 200-day moving average of $8.80. The stock has a market cap of $49.16 billion, a price-to-earnings ratio of -140.87, a P/E/G ratio of 4.74 and a beta of 0.66. Bayer Aktiengesellschaft has a 52-week low of $5.30 and a 52-week high of $13.00. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.